Samuel O'Brient

Samuel O'Brient

Expertise: Global Financial Markets, Macroeconomics and Geopolitics

Education: BA, Economics & Political Science, Sarah Lawrence College; MSc, International Politics, Trinity College Dublin

Awards & Accomplishments: Published in Curlew Quarterly. Quoted in Forbes. Interviewed by Foreign Policy.

About Samuel
Samuel O’Brient is a Reporter for InvestorPlace, where his work focuses primarily on financial markets, global economic trends, and public policy. O’Brient writes a weekly column on recent political news that investors should be following.

From his early days at InvestorPlace, O’Brient found himself drawn to the booming world of electric vehicles and green energy. His coverage of mining and other battery components has made him an expert source for industry publications. During his early years as an Economic Policy Analyst at U.S. Resist News, he gained expertise in international trade as the U.S.-China trade war dominated headlines. This in-depth research and analysis experience helped strengthen his prowess in all things political economy. O’Brient brings this expertise to work with him every day, thoughtfully analyzing how the daily happenings on the Capitol trickle down to Wall Street… and how retail investors can take action to profit.

An experienced journalist, editor, and economic policy analyst, O’Brient has spent his career guided by a deep passion for economic theory and policy. As a financial blogger on TipRanks, he has received 4.6 stars and is ranked in the top 10% of stock pickers.

O’Brient’s work on economic and tech policy has been curated by popular outlets Marker, OneZero and Gen.

He can be reached on LinkedIn and Muck Rack.

Recent Articles

Buy the Omicron Dip? Here’s What These JPMorgan Pros Are Saying.

A variant has cast doubt over markets, but several experts think investors should see it as an opportunity to buy the omicron dip.

BYSI Stock Alert: Bad News From the FDA Has BeyondSpring Tanking Today

BeyondSpring is falling hard after the FDA turned down a once-promising drug candidate. Here's why you shouldn't write off BYSI stock.

VBIV Stock Is Shooting Higher on Big FDA Vaccine Approval News

VBI Vaccines just got the green light from the FDA for its new Hepatitis B vaccine. VBIV stock is reacting well so far today.

NUZE Stock Alert: What’s Going on With Short Squeeze Play NuZee Today?

NuZee has been rising all day as short squeeze momentum propels it forward. Here's why you should be watching NUZE stock.

AERC Stock: AeroClean Tech Shares Plunge After Last Week’s Dazzling IPO Debut

AeroClean shocked markets last week with is impressive IPO. However, today saw AERC stock fall back down even faster.